全文获取类型
收费全文 | 283篇 |
免费 | 53篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 9篇 |
妇产科学 | 4篇 |
基础医学 | 36篇 |
口腔科学 | 2篇 |
临床医学 | 39篇 |
内科学 | 27篇 |
皮肤病学 | 2篇 |
神经病学 | 125篇 |
特种医学 | 24篇 |
外科学 | 11篇 |
综合类 | 16篇 |
预防医学 | 32篇 |
眼科学 | 3篇 |
药学 | 28篇 |
肿瘤学 | 4篇 |
出版年
2023年 | 4篇 |
2022年 | 2篇 |
2021年 | 3篇 |
2020年 | 5篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 4篇 |
2016年 | 3篇 |
2014年 | 5篇 |
2013年 | 10篇 |
2012年 | 7篇 |
2011年 | 14篇 |
2010年 | 7篇 |
2009年 | 9篇 |
2008年 | 14篇 |
2007年 | 22篇 |
2006年 | 16篇 |
2005年 | 25篇 |
2004年 | 9篇 |
2003年 | 12篇 |
2002年 | 14篇 |
2001年 | 7篇 |
2000年 | 15篇 |
1999年 | 15篇 |
1998年 | 6篇 |
1997年 | 8篇 |
1996年 | 12篇 |
1995年 | 12篇 |
1994年 | 6篇 |
1993年 | 12篇 |
1992年 | 4篇 |
1991年 | 9篇 |
1990年 | 7篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 4篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1975年 | 4篇 |
1973年 | 3篇 |
1971年 | 3篇 |
1970年 | 2篇 |
1963年 | 1篇 |
1962年 | 1篇 |
1961年 | 2篇 |
排序方式: 共有363条查询结果,搜索用时 0 毫秒
361.
Pieter A. van Doorn Peter Y. K. Van den Bergh Robert D. M. Hadden Bert Avau Patrik Vankrunkelsven Shahram Attarian Patricia H. Blomkwist-Markens David R. Cornblath H. Stephan Goedee Thomas Harbo Bart C. Jacobs Susumu Kusunoki Helmar C. Lehmann Richard A. Lewis Michael P. Lunn Eduardo Nobile-Orazio Luis Querol Yusuf A. Rajabally Thirugnanam Umapathi Haluk A. Topaloglu Hugh J. Willison 《European journal of neurology》2023,30(12):3646-3674
Guillain–Barré syndrome (GBS) is an acute polyradiculoneuropathy. Symptoms may vary greatly in presentation and severity. Besides weakness and sensory disturbances, patients may have cranial nerve involvement, respiratory insufficiency, autonomic dysfunction and pain. To develop an evidence-based guideline for the diagnosis and treatment of GBS, using Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology a Task Force (TF) of the European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) constructed 14 Population/Intervention/Comparison/Outcome questions (PICOs) covering diagnosis, treatment and prognosis of GBS, which guided the literature search. Data were extracted and summarised in GRADE Summaries of Findings (for treatment PICOs) or Evidence Tables (for diagnostic and prognostic PICOs). Statements were prepared according to GRADE Evidence-to-Decision (EtD) frameworks. For the six intervention PICOs, evidence-based recommendations are made. For other PICOs, good practice points (GPPs) are formulated. For diagnosis, the principal GPPs are: GBS is more likely if there is a history of recent diarrhoea or respiratory infection; CSF examination is valuable, particularly when the diagnosis is less certain; electrodiagnostic testing is advised to support the diagnosis; testing for anti-ganglioside antibodies is of limited clinical value in most patients with typical motor-sensory GBS, but anti-GQ1b antibody testing should be considered when Miller Fisher syndrome (MFS) is suspected; nodal–paranodal antibodies should be tested when autoimmune nodopathy is suspected; MRI or ultrasound imaging should be considered in atypical cases; and changing the diagnosis to acute-onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP) should be considered if progression continues after 8 weeks from onset, which occurs in around 5% of patients initially diagnosed with GBS. For treatment, the TF recommends intravenous immunoglobulin (IVIg) 0.4 g/kg for 5 days, in patients within 2 weeks (GPP also within 2–4 weeks) after onset of weakness if unable to walk unaided, or a course of plasma exchange (PE) 12–15 L in four to five exchanges over 1–2 weeks, in patients within 4 weeks after onset of weakness if unable to walk unaided. The TF recommends against a second IVIg course in GBS patients with a poor prognosis; recommends against using oral corticosteroids, and weakly recommends against using IV corticosteroids; does not recommend PE followed immediately by IVIg; weakly recommends gabapentinoids, tricyclic antidepressants or carbamazepine for treatment of pain; does not recommend a specific treatment for fatigue. To estimate the prognosis of individual patients, the TF advises using the modified Erasmus GBS outcome score (mEGOS) to assess outcome, and the modified Erasmus GBS Respiratory Insufficiency Score (mEGRIS) to assess the risk of requiring artificial ventilation. Based on the PICOs, available literature and additional discussions, we provide flow charts to assist making clinical decisions on diagnosis, treatment and the need for intensive care unit admission. 相似文献
362.
Susan K. Halstead Mark Jackson Ezio Bianchi Stefan Rupp Nicolas Granger Marika Menchetti Greta Galli Paul Freeman Adriana Kaczmarska Sofie F. M. Bhatti Josep Brocal Roberto José-López Andrea Tipold Rodrigo Gutierrez Quintana Edward J. Ives Theofanis Liatis Jasmin Nessler Clare Rusbridge Hugh J. Willison Angie Rupp 《Journal of the peripheral nervous system : JPNS》2023,28(1):32-40
Recent work identified anti-GM2 and anti-GalNAc-GD1a IgG ganglioside antibodies as biomarkers in dogs clinically diagnosed with acute canine polyradiculoneuritis, in turn considered a canine equivalent of Guillain-Barré syndrome. This study aims to investigate the serum prevalence of similar antibodies in cats clinically diagnosed with immune-mediated polyneuropathies. The sera from 41 cats clinically diagnosed with immune-mediated polyneuropathies (IPN), 9 cats with other neurological or neuromuscular disorders (ONM) and 46 neurologically normal cats (CTRL) were examined for the presence of IgG antibodies against glycolipids GM1, GM2, GD1a, GD1b, GalNAc-GD1a, GA1, SGPG, LM1, galactocerebroside and sulphatide. A total of 29/41 IPN-cats had either anti-GM2 or anti-GalNAc-GD1a IgG antibodies, with 24/29 cats having both. Direct comparison of anti-GM2 (sensitivity: 70.7%; specificity: 78.2%) and anti-GalNAc-GD1a (sensitivity: 70.7%; specificity: 70.9%) antibodies narrowly showed anti-GM2 IgG antibodies to be the better marker for identifying IPN-cats when compared to the combined ONM and CTRL groups (P = .049). Anti-GA1 and/or anti-sulphatide IgG antibodies were ubiquitously present across all sample groups, whereas antibodies against GM1, GD1a, GD1b, SGPG, LM1 and galactocerebroside were overall only rarely observed. Anti-GM2 and anti-GalNAc-GD1a IgG antibodies may serve as serum biomarkers for immune-mediated polyneuropathies in cats, as previously observed in dogs and humans. 相似文献
363.
Madeleine E. Cunningham Rhona McGonigal Jennifer A. Barrie Clare I. Campbell Denggao Yao Hugh J. Willison 《Journal of the peripheral nervous system : JPNS》2023,28(1):17-31
The major determinant of poor outcome in Guillain-Barré syndrome (GBS) is axonal degeneration. Pathways leading to primary axonal injury in the motor axonal variant are well established, whereas mechanisms of secondary axonal injury in acute inflammatory demyelinating polyneuropathy (AIDP) are unknown. We recently developed an autoantibody-and complement-mediated model of murine AIDP, in which prominent injury to glial membranes at the node of Ranvier results in severe disruption to paranodal components. Acutely, axonal integrity was maintained, but over time secondary axonal degeneration occurred. Herein, we describe the differential mechanisms underlying acute glial membrane injury and secondary axonal injury in this model. Ex vivo nerve-muscle explants were injured for either acute or extended periods with an autoantibody-and complement-mediated injury to glial paranodal membranes. This model was used to test several possible mechanisms of axon degeneration including calpain activation, and to monitor live axonal calcium signalling. Glial calpains induced acute disruption of paranodal membrane proteins in the absence of discernible axonal injury. Over time, we observed progressive axonal degeneration which was markedly attenuated by axon-specific calpain inhibition. Injury was unaffected by all other tested methods of protection. Trans-axolemmal diffusion of fluorescent proteins and live calcium imaging studies indirectly demonstrated the presence of nanoruptures in the axon membrane. This study outlines one mechanism by which secondary axonal degeneration arises in the AIDP variant of GBS where acute paranodal loop injury is prominent. The data also support the development of calpain inhibitors to attenuate both primary and secondary axonal degeneration in GBS. 相似文献